Striatum-Targeted Anhedonia Rapid Treatment (START): a novel transcranial magnetic stimulation paradigm for treating symptoms of anhedonia in depression
2021 Award: $38,280
Anhedonia, the inability to experience pleasure, is notoriously difficult to treat and predicts suicide risk. Thus, novel treatment paradigms are required to address this critical need in psychiatry. In a randomized clinical trial, we investigate a novel treatment paradigm and contribute to scientific knowledge of the neural basis of anhedonia.
Need/Problem: Anhedonia, or the inability to experience pleasure, is a core symptom of major depressive disorder that predicts suicide risk and can be exacerbated by some treatments. Symptoms of anhedonia are notoriously difficult to treat, so novel interventions and a better understanding of the neural basis of anhedonia are required.
Grant Summary: Patients with major depressive disorder and high symptoms of anhedonia will be recruited to participate in a double-blinded placebo-controlled randomized clinical trials that administers non-invasive brain stimulation to the prefrontal cortex in a rapid treatment paradigm.
Goals and Projected Outcomes: The proposed experiment will not only investigate the potential of a novel treatment paradigm to reduce symptoms of anhedonia in major depressive disorder, but also contribute to scientific knowledge of the neural and psychological basis of anhedonia.